https://www.live-feeds.com/feed/vir-ceo-sees-opportunity-to-do-more-deals-after-striking-1-9b-gilead-pact-for-dual-masked-tcesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/vir-ceo-sees-opportunity-to-do-more-deals-after-striking-1-9b-gilead-pact-for-dual-masked-tceshttps://www.live-feeds.com/feed/vir-ceo-sees-opportunity-to-do-more-deals-after-striking-1-9b-gilead-pact-for-dual-masked-tces#u130841Sun, 18 Oct 2026 06:25:45 +0000Vir Biotechnology and Gilead Sciences entered a multi-program collaboration to develop dual-masked T-cell engagers for solid tumors using Vir's PRO-XTEN masking platform. The deal is worth up to 1.9 billion dollars, including 90 million dollars upfront. Vir will manage discovery, design, and optimization, while Gilead will handle development, manufacturing, and commercialization for three candidates. Vir CEO Marianne De Backer stated the company sees opportunities for additional partnerships involving this technology while continuing to advance its own oncology programs.Why it mattersThe